What is the treatment for Staphylococcus (Staph) lugdunensis infections?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 27, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Staphylococcus lugdunensis Infections

Treat S. lugdunensis infections aggressively with the same approach as S. aureus infections, using beta-lactam antibiotics based on susceptibility testing, because this organism causes substantially more virulent disease than other coagulase-negative staphylococci with high rates of perivalvular extension, metastatic infection, and mortality. 1

Key Clinical Recognition

S. lugdunensis is NOT a typical coagulase-negative staphylococcus—it behaves like S. aureus:

  • When isolated from blood cultures, treat as a true pathogen rather than contamination 2
  • This organism causes aggressive infections with valve destruction, abscess formation, and metastatic spread similar to S. aureus 1, 3
  • Mortality and complication rates approach those of S. aureus endocarditis 1
  • Requires species-level identification through specialized testing (pyrrolidonyl aminopeptidase hydrolysis, MALDI-TOF, or PCR) 1

Antibiotic Selection

First-line therapy: Beta-lactam antibiotics based on susceptibility

  • Oxacillin-susceptible strains (majority): Use nafcillin, oxacillin, or cloxacillin at standard S. aureus dosing 1, 4
  • Cefazolin is an acceptable alternative 5, 4
  • S. lugdunensis remains highly susceptible to most antibiotics (86-96% oxacillin-susceptible) 6, 7, 3, 4
  • Beta-lactam therapy shows superior outcomes compared to vancomycin (92% vs 76% treatment success at 2 years for prosthetic joint infections) 4

Avoid vancomycin as first-line therapy unless the patient has a severe beta-lactam allergy or the isolate is methicillin-resistant 5, 4

Treatment Duration by Clinical Scenario

Catheter-Related Bloodstream Infection (CRBSI)

  • Manage identically to S. aureus CRBSI: Remove catheter and treat for 4-6 weeks 1, 8
  • Do NOT use the short 5-7 day regimen appropriate for other coagulase-negative staphylococci 1, 8
  • Obtain transesophageal echocardiography to exclude endocarditis 1

Infective Endocarditis

  • Duration: 4-6 weeks of parenteral beta-lactam therapy 1
  • Monitor closely for periannular extension and extracardiac spread 1
  • High surgical intervention rate due to valve destruction and abscess formation 1, 3
  • Do NOT add aminoglycosides—they increase renal toxicity without improving outcomes 5

Prosthetic Joint Infection

  • Surgical approach: Two-stage revision achieves 85% cure rate versus 33% for other approaches 9
  • Debridement alone or no surgery results in 44-100% relapse rates 9
  • Antibiotic duration: Prolonged parenteral beta-lactam therapy (median 38 days in successful cases) 9, 4
  • One-stage revision and antibiotic-only approaches have unacceptably high failure rates 9

Skin and Soft Tissue Infections

  • Oral antibiotics effective for uncomplicated cases: amoxicillin-clavulanate, cefuroxime axetil, or doxycycline 6, 7
  • Treatment duration: Standard course for skin infections (typically 7-14 days) 6, 7
  • 100% cure rate reported with appropriate antibiotic therapy 6
  • Common presentations: folliculitis, hidradenitis suppurativa, abscesses 6, 7

Critical Monitoring Requirements

All patients require:

  • Transesophageal echocardiography to exclude endocarditis, even with apparent localized infection 1
  • Serial blood cultures to document clearance 5
  • Close surveillance for metastatic complications (vertebral osteomyelitis, epidural abscess, septic arthritis) 1, 3

Common Pitfalls to Avoid

  • Do not dismiss as contaminant: Unlike other coagulase-negative staphylococci, S. lugdunensis in blood cultures represents true infection 2, 8
  • Do not use short-course therapy: Even for catheter-related infections, treat for 4-6 weeks like S. aureus 1, 8
  • Do not rely on vancomycin: Beta-lactams show superior outcomes 4
  • Do not attempt conservative management of prosthetic joint infections: Two-stage revision is necessary for cure 9
  • Do not skip echocardiography: The aggressive nature of this organism mandates cardiac imaging 1

Resistance Patterns

  • Penicillin resistance: 28.5% (beta-lactamase production) 6
  • Clindamycin resistance: 36% 6
  • Oxacillin resistance: 4-14% (mecA-negative in 95% of isolates) 3, 4
  • Remains susceptible to most other antibiotics including fluoroquinolones, rifampin, and linezolid 6, 3

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.